Research articles
ScienceAsia 51 (2023): 1-8 |doi:
10.2306/scienceasia1513-1874.2023.046
miR-222 enhances hepatocellular carcinoma cell proliferation,
migration, and anti-apoptosis via targeting PTEN
Fengxia Xua,?, Tianzhao Xub,?, Hui Songa,?, Guangli Lic, Xinyi Lid, Lanmei Zhoud, Xinghui Liua,*
ABSTRACT: Increasing evidence indicates that miRNAs affect the progression of hepatocellular carcinoma (HCC). The
target genes and binding sites of miR-222 were predicted by TargetScan website. RT-PCR was used to detect the
expression levels of miR-222 and Phosphatase and tensin homolog (PTEN) in HCC tissues and HCC cell lines (HCC
LM3, SMCC7721, and HepG2). CCK-8 assay, flow cytometry, scratch test, and Transwell test were used to detect the
proliferation, apoptosis, migration, and invasion capabilities of HCC cells following miR-222 modulation, respectively.
Western blotting was performed to analyze the effect of miR-222 inhibitor on the expression of PTEN, Bcl-2, and Bax.
The results showed that miR-222 expression was significantly up-regulated, while PTEN expression was significantly
down-regulated in HCC tissues and cell lines. miR-222 inhibitor significantly inhibited the proliferation, migration,
and invasion of HepG2 cells and promoted the apoptosis of HepG2 cells and the expression of PTEN. In addition,
miR-222 expression was negatively correlated with PTEN, and HCC patients with high miR-222 expression and low
PTEN expression were significantly associated with larger tumor size, well/moderate histological differentiation, and
metastasis. These results suggest that miR-222 inhibitor exerts an anticancer effect on HCC cells, possibly by targeting
the target gene PTEN, and provide a theoretical basis for potential new therapeutic targets for HCC.
Download PDF
Downloads Views
| a |
Department of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Pudong New Area,
Shanghai 200135 China |
| b |
Department of Central Laboratory, Zhoupu Hospital Affiliated to Shanghai University of Medicine and Health,
Pudong New Area, Shanghai 201318 China |
| c |
Postgraduate training base at Shanghai Gongli hospital, Ningxia medical university, Pudong New Area,
Shanghai 200135 China |
| d |
School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Yangpu District,
Shanghai 200093 China |
* Corresponding author, E-mail: syliuxh@163.com
Received 17 Apr 2024, Accepted 28 Apr 2025
|
